Vaxart Investors Can Tweak Stock Claims Over COVID Vaccine

By Craig Clough · May 13, 2021, 9:42 PM EDT

A group of investors suing Vaxart Inc. can amend their complaint to more clearly allege that the company artificially inflated its stock price through a press release with a deceptive headline...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

In re Vaxart, Inc. Securities Litigation

Case Number

3:20-cv-05949

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

August 24, 2020